These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26998904)

  • 21. Gleason Upgrading with Time in a Large Prostate Cancer Active Surveillance Cohort.
    Jain S; Loblaw A; Vesprini D; Zhang L; Kattan MW; Mamedov A; Jethava V; Sethukavalan P; Yu C; Klotz L
    J Urol; 2015 Jul; 194(1):79-84. PubMed ID: 25660208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.
    Gallina A; Maccagnano C; Suardi N; Capitanio U; Abdollah F; Raber M; Salonia A; Scattoni V; Rigatti P; Montorsi F; Briganti A
    BJU Int; 2012 Jul; 110(2 Pt 2):E64-8. PubMed ID: 22093108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer.
    Moussa AS; Li J; Soriano M; Klein EA; Dong F; Jones JS
    BJU Int; 2009 Jan; 103(1):43-8. PubMed ID: 18782303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database.
    Grossfeld GD; Chang JJ; Broering JM; Li YP; Lubeck DP; Flanders SC; Carroll PR
    J Urol; 2001 Mar; 165(3):851-6. PubMed ID: 11176485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience.
    Magheli A; Hinz S; Hege C; Stephan C; Jung K; Miller K; Lein M
    J Urol; 2010 Jan; 183(1):126-31. PubMed ID: 19913257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?
    Stav K; Judith S; Merald H; Leibovici D; Lindner A; Zisman A
    Urol Oncol; 2007; 25(5):383-6. PubMed ID: 17826654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
    Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
    BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
    Bul M; van den Bergh RC; Rannikko A; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Feb; 61(2):370-7. PubMed ID: 21704447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology.
    Chun FK; Steuber T; Erbersdobler A; Currlin E; Walz J; Schlomm T; Haese A; Heinzer H; McCormack M; Huland H; Graefen M; Karakiewicz PI
    Eur Urol; 2006 May; 49(5):820-6. PubMed ID: 16439050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of pathological upgrading in low-risk prostate cancer patients without hypointense lesions on an apparent diffusion coefficient map of multiparametric magnetic resonance imaging.
    Kang M; Song B; Lee I; Lee SE; Byun SS; Hong SK
    World J Urol; 2016 Nov; 34(11):1541-1546. PubMed ID: 27074937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate cancer volume at biopsy predicts clinically significant upgrading.
    Dong F; Jones JS; Stephenson AJ; Magi-Galluzzi C; Reuther AM; Klein EA
    J Urol; 2008 Mar; 179(3):896-900; discussion 900. PubMed ID: 18207180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should we replace the Gleason score with the amount of high-grade prostate cancer?
    Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
    Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.
    Kamrava M; Kishan AU; Margolis DJ; Huang J; Dorey F; Lieu P; Kupelian PA; Marks LS
    Pract Radiat Oncol; 2015; 5(6):411-6. PubMed ID: 26059510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer.
    Porcaro AB; Gallina S; Bianchi A; Cerrato C; Tafuri A; Rizzetto R; Amigoni N; Orlando R; Serafin E; Gozzo A; Migliorini F; Antoniolli SZ; Lacola V; De Marco V; Brunelli M; Cerruto MA; Siracusano S; Antonelli A
    Int Urol Nephrol; 2021 Dec; 53(12):2505-2515. PubMed ID: 34677784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
    Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
    Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
    Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
    J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients.
    Ploussard G; Isbarn H; Briganti A; Sooriakumaran P; Surcel CI; Salomon L; Freschi M; Mirvald C; van der Poel HG; Jenkins A; Ost P; van Oort IM; Yossepowitch O; Giannarini G; van den Bergh RC;
    Urol Oncol; 2015 Feb; 33(2):71.e1-9. PubMed ID: 25131660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.